Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2006 by Emory University. Recruitment status was Recruiting

First Received on September 14, 2005. Last Updated on February 7, 2006 History of Changes

Sponsor:	Emory University
Information provided by:	Emory University
ClinicalTrials.gov Identifier:	NCT00209131

Purpose

The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.

Condition
Urolithiasis

Study Type:	Observational
Study Design:	Observational Model: Defined Population Time Perspective: Longitudinal Time Perspective: Prospective
Official Title:	Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

Resource links provided by NLM:

MedlinePlus related topics: Shock

U.S. FDA Resources

Further study details as provided by Emory University:

Estimated Enrollment:	24
Study Start Date:	April 2005
Estimated Study Completion Date:	September 2005

Detailed Description:

Placebo blinded study examining the effects of Flomax on stone passage rates following SWL.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

urolithiasis undergoing SWL

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00209131

Contacts

Contact: Kenneth Ogan, MD

404-778-3038

kenneth_ogan@emoryhealthcare.org

Locations

United States, Georgia
Emory University	Recruiting
Atlanta, Georgia, United States, 30322
Contact: Kenneth Ogan, MD 404-778-3038 kenneth_ogan@emoryhealthcare.org

Sponsors and Collaborators

Emory University

Investigators

Principal Investigator:

Kenneth Ogan, MD

Emory University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00209131 History of Changes
Other Study ID Numbers:	IRB ID: 128-2005
Study First Received:	September 14, 2005
Last Updated:	February 7, 2006
Health Authority:	United States: Food and Drug Administration

Keywords provided by Emory University:

urolithiasis

Additional relevant MeSH terms:

Urolithiasis
Urologic Diseases

ClinicalTrials.gov processed this record on February 12, 2012